Skip to content

Integrating Animal-Assisted Therapy Into Trauma-Focused Cognitive-Behavioral Therapy for Maltreated Youth

Integrating Animal-Assisted Therapy Into Trauma-Focused Cognitive-Behavioral Therapy for Maltreated Youth: A Randomized Feasibility Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03135119
Acronym
TF-CBT+AAT
Enrollment
33
Registered
2017-05-01
Start date
2017-11-15
Completion date
2020-03-18
Last updated
2022-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Child Abuse, Posttraumatic Stress

Brief summary

This study will examine the incremental benefit of animal-assisted therapy (AAT) as an adjunct intervention when combined with Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT) for the treatment of maltreated youth. In addition, the development of therapeutic rapport and the intensity of stress experienced during treatment sessions will be examined as mediational mechanisms of treatment outcome. This project will help determine whether a larger study to test the beneficial effects of AAT for maltreated youth is feasible and warranted.

Detailed description

The eventual goal of this line of research is to determine whether, and through what mechanisms, Animal-Assisted Therapy (AAT) is beneficial for the treatment of maltreated youth. The current project is a feasibility study to determine if larger clinical trials are warranted. The specific aims of the current study are (1) to examine whether the integration of AAT into standard Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT) enhances treatment effectiveness, (2) to evaluate the tolerability and feasibility of AAT when integrated into TF-CBT, and (3) to evaluate hypothesized mediational processes that may explain observed positive effects for the integration of AAT. Maltreated youth may display myriad emotional and behavioral symptoms; prominent among these is posttraumatic stress (PTS). TF-CBT is a well-established evidence-based treatment for PTS and other symptoms subsequent to child maltreatment and, therefore, is a suitable intervention for this trial. Sixty (60) maltreated youth (ages 6-17) displaying elevated PTS will be assigned to receive TF-CBT or TF-CBT+AAT using a blocked randomization procedure. The TF-CBT protocol is the standard twelve 90-minute sessions typically used in research trials. Youth in the TF-CBT+AAT condition will receive the standard protocol with a certified service dog present in the room for each session and the youth will be allowed to interact with the dog during session. A pre-post design will be used to ascertain whether the addition of AAT prompts greater PTS reduction as well as greater improvements in other outcomes, including internalizing symptoms, externalizing symptoms, and emotion regulation. Outcome metrics include caregiver and youth-reported objective measures, and respiratory sinus arrhythmia (RSA) assessed via an electrocardiogram (ECG) during both a resting and stress reactivity paradigm. Feasibility metrics assessed include treatment satisfaction, ability to implement the TF-CBT techniques with a dog in the room, treatment disrupting events attributable to the dogs, and whether the dogs experience significant stress as a result of their participation. Stress experienced by the dog will be determined through RSA, salivary cortisol, and behavioral responses. Two prominent hypotheses regarding the mechanism of effect for AAT will be examined. First, therapeutic rapport will be assessed at multiple increments to determine whether the presence of the dog improved the quality or efficiency of development of rapport. Second, RSA will be recorded for the youth during treatment sessions to determine if the presence of the dog yielded a lower intensity of stress during the sessions. Both therapeutic rapport and level of in-session stress will be examined as mediating variables to determine whether either explained enhanced treatment outcomes. To improve the methodological rigor of the study, data will be collected by research assistants blinded to the youth's treatment condition and the same clinicians will implement both treatment conditions, thereby eliminating clinician-specific effects on outcomes.

Interventions

BEHAVIORALTF-CBT

TF-CBT is typically described as including 3 phases, each focusing on a common goal and encompassing a third of treatment (4 sessions). The first phase focuses on skills-building and includes psychoeducation, parenting skills training, relaxation skills training, affect modulation skills training, and cognitive coping skills training. The second phase involves focused gradual exposure activities, including construction of a narrative account of the child's maltreatment experiences and cognitive processing of maladaptive thoughts. The third phase emphasizes the child's mastery over environmental reminders of the maltreatment and includes sharing the trauma narrative with the caregiver, in vivo exposure to physical stimuli, and enhancing future development.

BEHAVIORALTF-CBT+AAT

TF-CBT, as described in the other arm, with animal-assisted therapy as an adjunct intervention. During the administration of TF-CBT, a certified service dog will be in the room and the participant may elect to interact with the dog as various points throughout the sessions.

Sponsors

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH
Milton S. Hershey Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

All individuals collecting and/or handling data will be masked.

Eligibility

Sex/Gender
ALL
Age
6 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* A caregiver willing to participate with the youth * An allegation of child maltreatment investigated by child protective services (CPS) or the police * A raw score of ≥ 39 (borderline or clinical elevation) on the caregiver- report version of the UCLA PTSD Reaction Index for the DSM-5.

Exclusion criteria

* Severe developmental delays and/or psychiatric problems that necessitate a higher level of care for the child. An allegation of child maltreatment investigated by child protective services (CPS) or the police * Intellectual deficits for the child (IQ \< 80 on a cognitive screener) * Caregiver inability to complete assessment measures due to psychiatric, cognitive, or other limitation * The available caregiver is suspected or known to have perpetrated maltreatment * A fear of dogs, a dog allergy, or any prior history of aggression toward animals for the child and/or caregiver

Design outcomes

Primary

MeasureTime frameDescription
Change in Scores on the UCLA Posttraumatic Stress Disorder Reaction IndexData were obtained at pre-treatment and every four weeks thereafter until the protocol was completed, **up to 13 weeks**. The last assessment completed, excluding the pre-treatment assessment, was considered post-treatment.This is a caregiver version of the measure designed to assess child/youth posttraumatic stress disorder (PTSD) symptoms. This is a 27-item questionnaire were the frequency of each item is reported using a scale ranging from 0 (Never) to 4 (Most Days), yielding a potential full scale score ranging from 0 to 108. For inclusion in this study, a score of at least 32 on the pre-treatment administration was required as this score denotes the borderline range for the measure. Lower scores indicate fewer PTSD symptoms are present.

Secondary

MeasureTime frameDescription
Change in Scores on the Strengths and Difficulties Questionnaire Emotional Symptoms SubscaleData were obtained at pre-treatment and every four weeks thereafter until the protocol was completed, **up to 13 weeks**. The last assessment completed, excluding the pre-treatment assessment, was considered post-treatment.The Strengths and Difficulties Questionnaire (SDQ) is a measure assessing the caregiver's observation of assorted emotional and behavioral concerns. This study utilized the Emotional Symptoms subscale, which collectively assesses symptoms of depression and anxiety. The subscale includes 5 items, each scored on a scale ranging from 0 (Never) to 2 (Certainly True). This results in possible total scores ranging from 0 to 10 with higher scores indicating a greater level of concern.
Change in Scores on the Screen for Child Anxiety Related DisordersData were obtained at pre-treatment and every four weeks thereafter until the protocol was completed, **up to 13 weeks**. The last assessment completed, excluding the pre-treatment assessment, was considered post-treatment.The Screen for Child Anxiety Related Disorders (SCARED) is a 41-item measure where the youth self-reports on concerns related to various forms of anxiety. Answer options range from 0 (Not True or Hardly Ever True) to 2 (Very Often or Very True), resulting in a possible total score between 0 and 82 with higher scores indicating greater concerns.
Change in Scores on the Moods and Feelings QuestionnaireData were obtained at pre-treatment and every four weeks thereafter until the protocol was completed, **up to 13 weeks**. The last assessment completed, excluding the pre-treatment assessment, was considered post-treatment.The Moods and Feelings Questionnaire (MFQ) is a 13-item measure that asks youth to report their own concerns with depression-related symptoms. Each item is answered with a 0 (Not True), 1 (Sometimes Ture), or 2 (True). The items are summed to create a total score that may range from 0 to 26, with higher scores denoting a greater level of depressive symptoms. .

Countries

United States

Participant flow

Recruitment details

Youth were recruited to participate in this study, although caregivers are necessary to complete the treatment protocol and caregiver-report was a primary method of evaluating outcome. No measures were collected on caregiver functioning or outcomes. Recruitment numbers and outcomes are strictly related to the youth participants.

Participants by arm

ArmCount
TF-CBT
Youth will receive standard Trauma-Focused Cognitive-Behavioral Therapy TF-CBT: TF-CBT is typically described as including 3 phases, each focusing on a common goal and encompassing a third of treatment (4 sessions). The first phase focuses on skills-building and includes psychoeducation, parenting skills training, relaxation skills training, affect modulation skills training, and cognitive coping skills training. The second phase involves focused gradual exposure activities, including construction of a narrative account of the child's maltreatment experiences and cognitive processing of maladaptive thoughts. The third phase emphasizes the child's mastery over environmental reminders of the maltreatment and includes sharing the trauma narrative with the caregiver, in vivo exposure to physical stimuli, and enhancing future development.
16
TF-CBT+AAT
Youth will received Trauma-Focused Cognitive-Behavioral Therapy with Animal-Assisted Therapy as an adjunct. TF-CBT+AAT: TF-CBT, as described in the other arm, with animal-assisted therapy as an adjunct intervention. During the administration of TF-CBT, a certified service dog will be in the room and the participant may elect to interact with the dog as various points throughout the sessions.
17
Total33

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyCOVID-19 Shutdown22
Overall StudyLost to Follow-up20
Overall StudyPhysician Decision11

Baseline characteristics

CharacteristicTF-CBT+AATTotalTF-CBT
Age, Continuous12.0 years
STANDARD_DEVIATION 2.89
11.79 years
STANDARD_DEVIATION 3.08
11.56 years
STANDARD_DEVIATION 3.35
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants7 Participants4 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
14 Participants26 Participants12 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
3 Participants7 Participants4 Participants
Race (NIH/OMB)
More than one race
2 Participants5 Participants3 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
12 Participants21 Participants9 Participants
Sex: Female, Male
Female
6 Participants11 Participants5 Participants
Sex: Female, Male
Male
11 Participants22 Participants11 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 160 / 17
other
Total, other adverse events
0 / 160 / 17
serious
Total, serious adverse events
0 / 160 / 17

Outcome results

Primary

Change in Scores on the UCLA Posttraumatic Stress Disorder Reaction Index

This is a caregiver version of the measure designed to assess child/youth posttraumatic stress disorder (PTSD) symptoms. This is a 27-item questionnaire were the frequency of each item is reported using a scale ranging from 0 (Never) to 4 (Most Days), yielding a potential full scale score ranging from 0 to 108. For inclusion in this study, a score of at least 32 on the pre-treatment administration was required as this score denotes the borderline range for the measure. Lower scores indicate fewer PTSD symptoms are present.

Time frame: Data were obtained at pre-treatment and every four weeks thereafter until the protocol was completed, **up to 13 weeks**. The last assessment completed, excluding the pre-treatment assessment, was considered post-treatment.

ArmMeasureGroupValue (MEAN)Dispersion
TF-CBTChange in Scores on the UCLA Posttraumatic Stress Disorder Reaction IndexPre-treatment44.63 units on a scaleStandard Deviation 12.38
TF-CBTChange in Scores on the UCLA Posttraumatic Stress Disorder Reaction IndexPost-treatment22.64 units on a scaleStandard Deviation 16.43
TF-CBT+AATChange in Scores on the UCLA Posttraumatic Stress Disorder Reaction IndexPre-treatment39.5 units on a scaleStandard Deviation 18.44
TF-CBT+AATChange in Scores on the UCLA Posttraumatic Stress Disorder Reaction IndexPost-treatment35.85 units on a scaleStandard Deviation 14.81
Secondary

Change in Scores on the Moods and Feelings Questionnaire

The Moods and Feelings Questionnaire (MFQ) is a 13-item measure that asks youth to report their own concerns with depression-related symptoms. Each item is answered with a 0 (Not True), 1 (Sometimes Ture), or 2 (True). The items are summed to create a total score that may range from 0 to 26, with higher scores denoting a greater level of depressive symptoms. .

Time frame: Data were obtained at pre-treatment and every four weeks thereafter until the protocol was completed, **up to 13 weeks**. The last assessment completed, excluding the pre-treatment assessment, was considered post-treatment.

ArmMeasureGroupValue (MEAN)Dispersion
TF-CBTChange in Scores on the Moods and Feelings QuestionnairePre-treatment9.13 units on a scaleStandard Deviation 5.6
TF-CBTChange in Scores on the Moods and Feelings QuestionnairePost-treatment5.91 units on a scaleStandard Deviation 5.54
TF-CBT+AATChange in Scores on the Moods and Feelings QuestionnairePre-treatment8.88 units on a scaleStandard Deviation 4.69
TF-CBT+AATChange in Scores on the Moods and Feelings QuestionnairePost-treatment8.85 units on a scaleStandard Deviation 6.12
Secondary

Change in Scores on the Screen for Child Anxiety Related Disorders

The Screen for Child Anxiety Related Disorders (SCARED) is a 41-item measure where the youth self-reports on concerns related to various forms of anxiety. Answer options range from 0 (Not True or Hardly Ever True) to 2 (Very Often or Very True), resulting in a possible total score between 0 and 82 with higher scores indicating greater concerns.

Time frame: Data were obtained at pre-treatment and every four weeks thereafter until the protocol was completed, **up to 13 weeks**. The last assessment completed, excluding the pre-treatment assessment, was considered post-treatment.

ArmMeasureGroupValue (MEAN)Dispersion
TF-CBTChange in Scores on the Screen for Child Anxiety Related DisordersPre-treatment39.64 units on a scaleStandard Deviation 18.04
TF-CBTChange in Scores on the Screen for Child Anxiety Related DisordersPost-treatment25.45 units on a scaleStandard Deviation 19.17
TF-CBT+AATChange in Scores on the Screen for Child Anxiety Related DisordersPre-treatment35.47 units on a scaleStandard Deviation 14.45
TF-CBT+AATChange in Scores on the Screen for Child Anxiety Related DisordersPost-treatment31.62 units on a scaleStandard Deviation 14.94
Secondary

Change in Scores on the Strengths and Difficulties Questionnaire Emotional Symptoms Subscale

The Strengths and Difficulties Questionnaire (SDQ) is a measure assessing the caregiver's observation of assorted emotional and behavioral concerns. This study utilized the Emotional Symptoms subscale, which collectively assesses symptoms of depression and anxiety. The subscale includes 5 items, each scored on a scale ranging from 0 (Never) to 2 (Certainly True). This results in possible total scores ranging from 0 to 10 with higher scores indicating a greater level of concern.

Time frame: Data were obtained at pre-treatment and every four weeks thereafter until the protocol was completed, **up to 13 weeks**. The last assessment completed, excluding the pre-treatment assessment, was considered post-treatment.

ArmMeasureGroupValue (MEAN)Dispersion
TF-CBTChange in Scores on the Strengths and Difficulties Questionnaire Emotional Symptoms SubscalePre-treatment6.5 units on a scaleStandard Deviation 2.58
TF-CBTChange in Scores on the Strengths and Difficulties Questionnaire Emotional Symptoms SubscalePost-treatment4.0 units on a scaleStandard Deviation 3
TF-CBT+AATChange in Scores on the Strengths and Difficulties Questionnaire Emotional Symptoms SubscalePre-treatment7.65 units on a scaleStandard Deviation 2
TF-CBT+AATChange in Scores on the Strengths and Difficulties Questionnaire Emotional Symptoms SubscalePost-treatment5.08 units on a scaleStandard Deviation 1.85

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026